HeartSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartSciences Inc. on June 3, 2025, covering events reported as of May 28, 2025. The filing details the formalization of a capital raising initiative previously disclosed in February 2025, specifically the entry into a material definitive agreement with a placement agent and the official designation of a new class of preferred stock.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. Instead, it outlines the terms of a proposed equity offering:
- Offering Size: Up to 4,285,714 Units for a maximum gross amount of $15,000,000.
- Offering Price: $3.50 per Unit.
- Unit Composition: One share of Series D Preferred Stock and one Warrant to purchase one share of Common Stock.
- Warrant Terms: Exercise price of $5.00 per share.
- Placement Agent Fees: 7% cash fee of gross proceeds plus warrants to purchase 3% of total Units sold (Agent Unit Warrants) at an exercise price of $4.375.
Material Changes and Corporate Actions
The primary material change reported is the execution of the Selling Agency Agreement with Digital Offering, LLC, effective March 10, 2025, on a "best efforts" basis. Additionally, on May 28, 2025, the Company received confirmation from the Texas Secretary of State that the Certificate of Designations for the Series D Convertible Preferred Stock was filed and became effective on May 21, 2025. This action legally established the 4,285,714 shares of Series D Preferred Stock required for the Offering.
Outlook, Risks, and Management Commentary
The filing indicates the Offering is being conducted on a "best efforts" basis, implying no guarantee that the full $15,000,000 will be raised. The Placement Agent Agreement includes customary representations, warranties, and indemnification provisions. The document explicitly states that the agreement's terms are for the benefit of the contracting parties and should be read in conjunction with the Company's periodic reports for broader business context. No specific forward-looking guidance on revenue or operational milestones is provided in this text.
Investor Verification Checklist
- Verify the current status of the Offering (e.g., amount sold to date) in subsequent filings or press releases.
- Review the full text of the Placement Agent Agreement (Exhibit 10.1) for specific termination rights and expense reimbursement details.
- Examine the Certificate of Designations (Exhibit 4.1) for specific conversion rights, dividend preferences, and liquidation priorities of the Series D Preferred Stock.
- Confirm the Company's current cash position and burn rate in the most recent 10-Q or 10-K to assess the necessity and timing of this capital raise.
- Check for any amendments to the Form 1-A Offering Statement that may alter the offering terms described herein.